Ascentage Pharma Group InternationalAAPG
Price (close)
$14.86
Market cap
$1.4B
P/E
—
Revenue (FY)
$980.6M
Net income
-$405.4M
Dividend yield
—
1-year total return
-60.7%
Net margin
-41.3%
Revenue growth
341.8%
Debt / equity
3.37x
What Ascentage Pharma Group International does.
we fail to comply with our obligations in the agreements under which we license intellectual property rights to or from third parties
or otherwise experience disruptions to our business relationships with our licensors or licensees, we could lose license rights that
are heavily reliant upon licenses from third parties to certain patent rights and proprietary technology that are important to or necessary
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | — | $209.7M | $222.0M | $980.6M |
| Net income | — | -$882.9M | -$925.6M | -$405.4M |
| Free cash flow | — | -$857.2M | -$772.2M | -$135.6M |
More on AAPG.
- Ascentage Pharma Group International summary
- Ascentage Pharma Group International financial statements
- Ascentage Pharma Group International key metrics
- Ascentage Pharma Group International health scores and style box
- Ascentage Pharma Group International earnings
- Ascentage Pharma Group International dividends
- Ascentage Pharma Group International valuation
- Ascentage Pharma Group International ownership and insiders
- Ascentage Pharma Group International peers
Figures from Ascentage Pharma Group International's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.